Is Celestica The Best AI Stock to Buy Now?
Technology and hardware business Celestica (NYSE:CLS) has seen massive upward…
Buy
55
ROIV Quote, Financials, Valuation and Earnings
Last price:
$27.03
Seasonality move
:
-7.14%
Day range:
$26.23 - $26.83
52-week range:
$8.73 - $27.94
Dividend yield:
0%
P/E ratio:
1.91x
P/S ratio:
1,373.87x
P/B ratio:
4.43x
Volume:
4.4M
Avg. volume:
6.9M
1-year change:
153.11%
Market cap:
$18.9B
Revenue:
$29.1M
EPS (TTM):
-$1.17
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
ROIV
Roivant Sciences Ltd.
|
$6.1M | -$0.31 | -44.18% | -7.85% | $31.73 |
|
GSK
GSK Plc
|
$6.1B | $0.62 | 9.57% | 17.04% | $57.48 |
|
IMVT
Immunovant, Inc.
|
-- | -$0.69 | -- | -9.61% | $40.63 |
|
KNSA
Kiniksa Pharmaceuticals International Plc
|
$200.9M | $0.37 | 52.45% | -62.86% | $55.00 |
|
SLNCF
Silence Therapeutics Plc
|
$1.6M | -$0.15 | 700.8% | -12.5% | -- |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
ROIV
Roivant Sciences Ltd.
|
$26.45 | $31.73 | $18.9B | 1.91x | $0.00 | 0% | 1,373.87x |
|
GSK
GSK Plc
|
$58.93 | $57.48 | $118.3B | 16.08x | $0.43 | 2.89% | 2.81x |
|
IMVT
Immunovant, Inc.
|
$25.75 | $40.63 | $5.2B | -- | $0.00 | 0% | -- |
|
KNSA
Kiniksa Pharmaceuticals International Plc
|
$45.37 | $55.00 | $3.4B | 101.20x | $0.00 | 0% | 5.81x |
|
SLNCF
Silence Therapeutics Plc
|
$1.60 | -- | $226.7M | -- | $0.00 | 0% | 112.71x |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
ROIV
Roivant Sciences Ltd.
|
2.49% | 0.862 | 0.68% | 29.83x |
|
GSK
GSK Plc
|
51.97% | -0.225 | 24.36% | 0.51x |
|
IMVT
Immunovant, Inc.
|
-- | 1.837 | -- | 15.03x |
|
KNSA
Kiniksa Pharmaceuticals International Plc
|
1.78% | -0.635 | 0.33% | 3.27x |
|
SLNCF
Silence Therapeutics Plc
|
0.25% | 4.622 | 0.09% | 5.88x |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
ROIV
Roivant Sciences Ltd.
|
$608K | -$339.2M | -19.48% | -19.87% | -16966.13% | -$191.5M |
|
GSK
GSK Plc
|
$8B | $1.3B | 19.46% | 43.01% | 11.2% | $1.4B |
|
IMVT
Immunovant, Inc.
|
-$101K | -$114.4M | -73.11% | -73.12% | -- | -$92.3M |
|
KNSA
Kiniksa Pharmaceuticals International Plc
|
$97.3M | $24M | 7.44% | 7.6% | 13.28% | $33M |
|
SLNCF
Silence Therapeutics Plc
|
-$20.5K | -$23.7M | -101.67% | -101.79% | -14881.13% | -$11M |
Roivant Sciences Ltd. vs. Competitors
-
Which has Higher Returns ROIV or GSK?
GSK Plc has a net margin of -15692.9% compared to Roivant Sciences Ltd.'s net margin of 8.44%. Roivant Sciences Ltd.'s return on equity of -19.87% beat GSK Plc's return on equity of 43.01%.
Company Gross Margin Earnings Per Share Invested Capital ROIVRoivant Sciences Ltd.30.42% -$0.38 $5.1B GSKGSK Plc69.38% $0.41 $45.3B -
What do Analysts Say About ROIV or GSK?
Roivant Sciences Ltd. has a consensus price target of $31.73, signalling upside risk potential of 19.95%. On the other hand GSK Plc has an analysts' consensus of $57.48 which suggests that it could fall by -4.87%. Given that Roivant Sciences Ltd. has higher upside potential than GSK Plc, analysts believe Roivant Sciences Ltd. is more attractive than GSK Plc.
Company Buy Ratings Hold Ratings Sell Ratings ROIVRoivant Sciences Ltd.9 1 0 GSKGSK Plc1 6 1 -
Is ROIV or GSK More Risky?
Roivant Sciences Ltd. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison GSK Plc has a beta of 0.477, suggesting its less volatile than the S&P 500 by 52.337%.
-
Which is a Better Dividend Stock ROIV or GSK?
Roivant Sciences Ltd. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. GSK Plc offers a yield of 2.89% to investors and pays a quarterly dividend of $0.43 per share. Roivant Sciences Ltd. pays -- of its earnings as a dividend. GSK Plc pays out 47.15% of its earnings as a dividend. GSK Plc's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.
-
Which has Better Financial Ratios ROIV or GSK?
Roivant Sciences Ltd. quarterly revenues are $2M, which are smaller than GSK Plc quarterly revenues of $11.5B. Roivant Sciences Ltd.'s net income of -$313.7M is lower than GSK Plc's net income of $966.8M. Notably, Roivant Sciences Ltd.'s price-to-earnings ratio is 1.91x while GSK Plc's PE ratio is 16.08x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Roivant Sciences Ltd. is 1,373.87x versus 2.81x for GSK Plc. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income ROIVRoivant Sciences Ltd.1,373.87x 1.91x $2M -$313.7M GSKGSK Plc2.81x 16.08x $11.5B $966.8M
-
Which has Higher Returns ROIV or IMVT?
Immunovant, Inc. has a net margin of -15692.9% compared to Roivant Sciences Ltd.'s net margin of --. Roivant Sciences Ltd.'s return on equity of -19.87% beat Immunovant, Inc.'s return on equity of -73.12%.
Company Gross Margin Earnings Per Share Invested Capital ROIVRoivant Sciences Ltd.30.42% -$0.38 $5.1B IMVTImmunovant, Inc.-- -$0.61 $986.1M -
What do Analysts Say About ROIV or IMVT?
Roivant Sciences Ltd. has a consensus price target of $31.73, signalling upside risk potential of 19.95%. On the other hand Immunovant, Inc. has an analysts' consensus of $40.63 which suggests that it could grow by 57.77%. Given that Immunovant, Inc. has higher upside potential than Roivant Sciences Ltd., analysts believe Immunovant, Inc. is more attractive than Roivant Sciences Ltd..
Company Buy Ratings Hold Ratings Sell Ratings ROIVRoivant Sciences Ltd.9 1 0 IMVTImmunovant, Inc.11 4 0 -
Is ROIV or IMVT More Risky?
Roivant Sciences Ltd. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Immunovant, Inc. has a beta of 0.541, suggesting its less volatile than the S&P 500 by 45.89%.
-
Which is a Better Dividend Stock ROIV or IMVT?
Roivant Sciences Ltd. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Immunovant, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Roivant Sciences Ltd. pays -- of its earnings as a dividend. Immunovant, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios ROIV or IMVT?
Roivant Sciences Ltd. quarterly revenues are $2M, which are larger than Immunovant, Inc. quarterly revenues of --. Roivant Sciences Ltd.'s net income of -$313.7M is lower than Immunovant, Inc.'s net income of -$110.6M. Notably, Roivant Sciences Ltd.'s price-to-earnings ratio is 1.91x while Immunovant, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Roivant Sciences Ltd. is 1,373.87x versus -- for Immunovant, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income ROIVRoivant Sciences Ltd.1,373.87x 1.91x $2M -$313.7M IMVTImmunovant, Inc.-- -- -- -$110.6M
-
Which has Higher Returns ROIV or KNSA?
Kiniksa Pharmaceuticals International Plc has a net margin of -15692.9% compared to Roivant Sciences Ltd.'s net margin of 10.19%. Roivant Sciences Ltd.'s return on equity of -19.87% beat Kiniksa Pharmaceuticals International Plc's return on equity of 7.6%.
Company Gross Margin Earnings Per Share Invested Capital ROIVRoivant Sciences Ltd.30.42% -$0.38 $5.1B KNSAKiniksa Pharmaceuticals International Plc53.78% $0.23 $545.1M -
What do Analysts Say About ROIV or KNSA?
Roivant Sciences Ltd. has a consensus price target of $31.73, signalling upside risk potential of 19.95%. On the other hand Kiniksa Pharmaceuticals International Plc has an analysts' consensus of $55.00 which suggests that it could grow by 21.23%. Given that Kiniksa Pharmaceuticals International Plc has higher upside potential than Roivant Sciences Ltd., analysts believe Kiniksa Pharmaceuticals International Plc is more attractive than Roivant Sciences Ltd..
Company Buy Ratings Hold Ratings Sell Ratings ROIVRoivant Sciences Ltd.9 1 0 KNSAKiniksa Pharmaceuticals International Plc6 0 0 -
Is ROIV or KNSA More Risky?
Roivant Sciences Ltd. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Kiniksa Pharmaceuticals International Plc has a beta of 0.060, suggesting its less volatile than the S&P 500 by 94.045%.
-
Which is a Better Dividend Stock ROIV or KNSA?
Roivant Sciences Ltd. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Kiniksa Pharmaceuticals International Plc offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Roivant Sciences Ltd. pays -- of its earnings as a dividend. Kiniksa Pharmaceuticals International Plc pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios ROIV or KNSA?
Roivant Sciences Ltd. quarterly revenues are $2M, which are smaller than Kiniksa Pharmaceuticals International Plc quarterly revenues of $180.9M. Roivant Sciences Ltd.'s net income of -$313.7M is lower than Kiniksa Pharmaceuticals International Plc's net income of $18.4M. Notably, Roivant Sciences Ltd.'s price-to-earnings ratio is 1.91x while Kiniksa Pharmaceuticals International Plc's PE ratio is 101.20x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Roivant Sciences Ltd. is 1,373.87x versus 5.81x for Kiniksa Pharmaceuticals International Plc. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income ROIVRoivant Sciences Ltd.1,373.87x 1.91x $2M -$313.7M KNSAKiniksa Pharmaceuticals International Plc5.81x 101.20x $180.9M $18.4M
-
Which has Higher Returns ROIV or SLNCF?
Silence Therapeutics Plc has a net margin of -15692.9% compared to Roivant Sciences Ltd.'s net margin of -13181.13%. Roivant Sciences Ltd.'s return on equity of -19.87% beat Silence Therapeutics Plc's return on equity of -101.79%.
Company Gross Margin Earnings Per Share Invested Capital ROIVRoivant Sciences Ltd.30.42% -$0.38 $5.1B SLNCFSilence Therapeutics Plc-12.89% -$0.15 $74.2M -
What do Analysts Say About ROIV or SLNCF?
Roivant Sciences Ltd. has a consensus price target of $31.73, signalling upside risk potential of 19.95%. On the other hand Silence Therapeutics Plc has an analysts' consensus of -- which suggests that it could fall by --. Given that Roivant Sciences Ltd. has higher upside potential than Silence Therapeutics Plc, analysts believe Roivant Sciences Ltd. is more attractive than Silence Therapeutics Plc.
Company Buy Ratings Hold Ratings Sell Ratings ROIVRoivant Sciences Ltd.9 1 0 SLNCFSilence Therapeutics Plc1 0 0 -
Is ROIV or SLNCF More Risky?
Roivant Sciences Ltd. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Silence Therapeutics Plc has a beta of 0.776, suggesting its less volatile than the S&P 500 by 22.438%.
-
Which is a Better Dividend Stock ROIV or SLNCF?
Roivant Sciences Ltd. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Silence Therapeutics Plc offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Roivant Sciences Ltd. pays -- of its earnings as a dividend. Silence Therapeutics Plc pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios ROIV or SLNCF?
Roivant Sciences Ltd. quarterly revenues are $2M, which are larger than Silence Therapeutics Plc quarterly revenues of $159K. Roivant Sciences Ltd.'s net income of -$313.7M is lower than Silence Therapeutics Plc's net income of -$21M. Notably, Roivant Sciences Ltd.'s price-to-earnings ratio is 1.91x while Silence Therapeutics Plc's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Roivant Sciences Ltd. is 1,373.87x versus 112.71x for Silence Therapeutics Plc. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income ROIVRoivant Sciences Ltd.1,373.87x 1.91x $2M -$313.7M SLNCFSilence Therapeutics Plc112.71x -- $159K -$21M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Will AI Disrupt SaaS Software Stocks?
Since January 28th, software stocks in the United States have…
Why Is Meta Stock Going Higher?
Over the last five days, shares of Instagram and Facebook…
Stock Ideas
Buy
51
Is NVDA Stock a Buy?
Market Cap: $4.4T
P/E Ratio: 62x
Sell
43
Is AAPL Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 34x
Sell
44
Is GOOG Stock a Buy?
Market Cap: $3.7T
P/E Ratio: 28x
Alerts
Buy
77
CPS alert for Feb 17
Cooper-Standard Holdings, Inc. [CPS] is down 2.63% over the past day.
Buy
58
TPH alert for Feb 17
Tri Pointe Homes, Inc. [TPH] is down 0.17% over the past day.
Sell
20
IRON alert for Feb 17
Disc Medicine, Inc. [IRON] is up 15.21% over the past day.
